PM BUZZ

Through our partnership with Diaceutics, Arris Partners is pleased to offer the Personalized Medicine (PM) Buzz. Compiled and curated from top global resources, the PM Buzz is a monthly snapshot of the latest news, industry developments and headline stories in the world of personalized (precision) medicine.

Diaceutics is a global group of experts from the laboratory, diagnostic and pharmaceutical industries with the goal of helping pharmaceutical companies integrate diagnostic testing into their treatment pathways. Diaceutics is empowered through a real-time flow of testing data from their worldwide laboratory network which they use to help their pharma clients understand and leverage the diagnostic landscape.

What’s happening in PM industry

Keytruda gets first-ever biomarker-specific approval read on…

Roche’s VENTANA PD-L1 (SP263) assay gains CE label expansion to inform treatment decisions in lung cancer patients being considered for Keytruda (pembrolizumab) immunotherapy read on…

Leica Biosystems applauds FDA Primary Diagnosis clearance as a step forward in clinical acceptance of digital pathology read on…

Cancer screening firm Guardant Health raises $360 million to sequence tumor DNA of 1 million patients read on…

Thermo Fisher Scientific signs development agreement with Agios Pharmaceuticals for Next-Generation Sequencing oncology companion diagnostic in cholangiocarcinoma read on…

Subscribe to receive future PM Buzz Reports.